Cargando…

Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma

BACKGROUND: To determine the clinical value of hepatobiliary phase (HBP) hypointensity for noninvasive diagnosis of hepatocellular carcinoma (HCC). METHODS: A total of 246 high-risk patients with 263 selected nodules (126 HCCs, 137 non-HCCs) undergoing gadobenate dimeglumine (Gd-BOPTA)-enhanced magn...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yueming, Chen, Jianwei, Weng, Shuping, Yan, Chuan, Ye, Rongping, Zhu, Yuemin, Wen, Liting, Cao, Dairong, Hong, Jinsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859813/
https://www.ncbi.nlm.nih.gov/pubmed/33553348
http://dx.doi.org/10.21037/atm.2020.02.38
_version_ 1783646817894793216
author Li, Yueming
Chen, Jianwei
Weng, Shuping
Yan, Chuan
Ye, Rongping
Zhu, Yuemin
Wen, Liting
Cao, Dairong
Hong, Jinsheng
author_facet Li, Yueming
Chen, Jianwei
Weng, Shuping
Yan, Chuan
Ye, Rongping
Zhu, Yuemin
Wen, Liting
Cao, Dairong
Hong, Jinsheng
author_sort Li, Yueming
collection PubMed
description BACKGROUND: To determine the clinical value of hepatobiliary phase (HBP) hypointensity for noninvasive diagnosis of hepatocellular carcinoma (HCC). METHODS: A total of 246 high-risk patients with 263 selected nodules (126 HCCs, 137 non-HCCs) undergoing gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) were included in the study. Imaging-based diagnoses of small (≤3 cm) and large (>3 cm) HCCs were made using the following 4 criteria: (I) non-rim arterial phase hyper-enhancement (APHE) plus hypointensity on the portal venous phase (PVP); (II) non-rim APHE plus hypointensity on the PVP and/or transitional phase (TP); (III) non-rim APHE plus hypointensity on the PVP and/or TP and/or HBP; (IV) criterion 3 plus non-LR-1/2/M. Based on typical imaging features, LR-1, LR-2, or LR-M (if definitely benign, probably benign, malignant but not HCC specific, respectively) were defined according to the Liver Imaging Reporting and Data System (LI-RADS). Sensitivities and specificities of imaging criteria were calculated and compared using McNemar’s test. RESULTS: Among the diagnostic criteria for small HCCs, criterion 3 and 4, which included HBP hypointensity, showed significantly higher sensitivities (96.4% and 94.6%, respectively) than criterion 1 (58.9%, P<0.001 for both). Moreover, criterion 4, which included HBP hypointensity and ancillary features, showed significantly higher specificity (94.7%) than criterion 3 (66.7%, P<0.001) and comparable specificity to criterion 1 (97.4%, P=0.375), achieving the highest accuracies (94.7%). The diagnostic performance of criterion 4 for large HCCs was similar to that for small HCCs. CONCLUSIONS: HBP hypointensity acquired from Gd-BOPTA-MRI can improve sensitivity and maintain high specificity in the diagnosis of both small and large HCCs after excluding benignities or non-HCC malignancies according to characteristic imaging features.
format Online
Article
Text
id pubmed-7859813
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78598132021-02-05 Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma Li, Yueming Chen, Jianwei Weng, Shuping Yan, Chuan Ye, Rongping Zhu, Yuemin Wen, Liting Cao, Dairong Hong, Jinsheng Ann Transl Med Original Article BACKGROUND: To determine the clinical value of hepatobiliary phase (HBP) hypointensity for noninvasive diagnosis of hepatocellular carcinoma (HCC). METHODS: A total of 246 high-risk patients with 263 selected nodules (126 HCCs, 137 non-HCCs) undergoing gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) were included in the study. Imaging-based diagnoses of small (≤3 cm) and large (>3 cm) HCCs were made using the following 4 criteria: (I) non-rim arterial phase hyper-enhancement (APHE) plus hypointensity on the portal venous phase (PVP); (II) non-rim APHE plus hypointensity on the PVP and/or transitional phase (TP); (III) non-rim APHE plus hypointensity on the PVP and/or TP and/or HBP; (IV) criterion 3 plus non-LR-1/2/M. Based on typical imaging features, LR-1, LR-2, or LR-M (if definitely benign, probably benign, malignant but not HCC specific, respectively) were defined according to the Liver Imaging Reporting and Data System (LI-RADS). Sensitivities and specificities of imaging criteria were calculated and compared using McNemar’s test. RESULTS: Among the diagnostic criteria for small HCCs, criterion 3 and 4, which included HBP hypointensity, showed significantly higher sensitivities (96.4% and 94.6%, respectively) than criterion 1 (58.9%, P<0.001 for both). Moreover, criterion 4, which included HBP hypointensity and ancillary features, showed significantly higher specificity (94.7%) than criterion 3 (66.7%, P<0.001) and comparable specificity to criterion 1 (97.4%, P=0.375), achieving the highest accuracies (94.7%). The diagnostic performance of criterion 4 for large HCCs was similar to that for small HCCs. CONCLUSIONS: HBP hypointensity acquired from Gd-BOPTA-MRI can improve sensitivity and maintain high specificity in the diagnosis of both small and large HCCs after excluding benignities or non-HCC malignancies according to characteristic imaging features. AME Publishing Company 2021-01 /pmc/articles/PMC7859813/ /pubmed/33553348 http://dx.doi.org/10.21037/atm.2020.02.38 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, Yueming
Chen, Jianwei
Weng, Shuping
Yan, Chuan
Ye, Rongping
Zhu, Yuemin
Wen, Liting
Cao, Dairong
Hong, Jinsheng
Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
title Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
title_full Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
title_fullStr Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
title_full_unstemmed Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
title_short Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
title_sort hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859813/
https://www.ncbi.nlm.nih.gov/pubmed/33553348
http://dx.doi.org/10.21037/atm.2020.02.38
work_keys_str_mv AT liyueming hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT chenjianwei hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT wengshuping hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT yanchuan hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT yerongping hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT zhuyuemin hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT wenliting hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT caodairong hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma
AT hongjinsheng hepatobiliaryphasehypointensityongadobenatedimeglumineenhancedmagneticresonanceimagingmayimprovethediagnosisofhepatocellularcarcinoma